



FINANCIAL TEAR SHEET

Corporate Profile

Apricus is committed to developing sexual health therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

Stock Performance

APRI (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$1.08
Change (%)	▼ 0.02 (1.82%)
Volume	90,097
52 Week High	\$4.94
52 Week Low	\$0.86
Market Cap	\$8,506,526
Rolling EPS	-1.21
PE Ratio	0
Shares Outstanding	7,733,205

Data as of 07/21/17 3:59 p.m. ET



Recent Headlines

05/11/17
[Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results](#)

05/04/17
[Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study](#)

05/04/17
[Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/16/17	SC 13G
06/05/17	4
06/05/17	4
06/05/17	4

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)

© Apricus Biosciences, Inc.